BHIC is a special opportunity for Birmingham and the West Midlands. It will create thousands of jobs and opportunities for new and existing businesses to thrive. It will provide cutting-edge innovation facilities, building on the area’s nationally recognised strengths in healthcare data, genomics medicine and diagnostics, medical technologies and clinical trials.
BHIC will create an environment that will help businesses to form, collaborate and grow. It will establish a new platform to advance life-saving health innovations and enable companies to access the clinical market faster. The plans are being developed in collaboration with Birmingham Health Partners (BHP), a strategic alliance between the University of Birmingham and two renowned NHS Trusts: University Hospitals Birmingham and Birmingham’s Women’s & Children’s. BHIC will facilitate pioneering and life changing work. It will enable productive interactions between clinicians, academics, industry and patients to accelerate the field of personalised, precision medicine. The timing has never been more important for this type of development and Birmingham is one of the only global cities truly equipped to deliver co-located and integrated facilities like this.
BHIC will deliver a number of benefits to the local area and the region including:
Innovative medical treatments to the NHS and patients in the West Midlands and across the UK
Around £400m GVA to the local economy per year
Up to 10,000 new jobs are likely to be supported in the regional economy upon completion, up to 3,000 of these will be on-site jobs
Approximately 657,000 sq ft (net internal area) of lab and office space
Flexible space for companies of varying scales and disciplines
The regeneration of a brownfield site in need of investment
The first phase of development will include Birmingham Precision Medicine Centre (BPMC), a unique centre designed to deliver a flexible and comprehensive service to address industry needs for translational medicine. It will be equipped to support, enable and facilitate every step of the drug development pipeline. Professor David Wraith, Director of the BPMC and the Institute of Immunology and Immunotherapy explains in the video opposite.
The University of Birmingham:10 acres of land on which Birmingham Health Innovation Campus is located is owned by the University of Birmingham. The University has appointed Bruntwood SciTech, the UK’s leading creator of innovation districts to take a long lease to develop Birmingham Health Innovation Campus in line with the University’s vision for the campus, in collaboration with Birmingham Health Partners (BHP). The first three floors of this building will be occupied by the University of Birmingham’s Precision Health Technologies Accelerator (PHTA). This will incorporate Birmingham Precision Medicine Centre (BPMC).
Bruntwood SciTech: Bruntwood SciTech is a 50:50 joint venture between Bruntwood and Legal & General. Bruntwood SciTech owns the largest portfolio of science and technology assets in the UK including the Innovation Birmingham Campus, Alderley Park and Manchester Science Park.
Birmingham Health Partners: Birmingham Health Partners is a strategic alliance between the University of Birmingham and two NHS Foundation Trusts – Birmingham Women’s & Children’s, and University Hospitals Birmingham.